| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
167,290,000 |
| Market
Cap: |
182.35(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6061 - $2.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile X4 Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of therapeutics for the treatment of rare diseases. Co.'s primary product candidate is mavorixafor, a small molecule chemokine receptor type 4 (CXCR4) antagonist that inhibits receptor binding by CXCL12, the cognate ligand of CXCR4. Co. is conducting clinical trials of mavorixafor: for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome, a rare primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene; and in people with chronic neutropenia and Waldenstrom's macroglobulinemia, a rare B-cell lymphoproliferative disorder.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
25,000 |
25,000 |
| Total Buy Value |
$0 |
$0 |
$29,875 |
$29,875 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
185,708 |
185,708 |
353,799 |
624,831 |
| Total Sell Value |
$170,713 |
$170,713 |
$383,960 |
$557,665 |
| Total People Sold |
4 |
4 |
5 |
6 |
| Total Sell Transactions |
8 |
8 |
19 |
42 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mostafa Adam S. |
Chief Financial Officer |
• – – |
2023-06-15 |
4 |
AS |
$2.22 |
$12,026 |
D/D |
(5,417) |
88,279 |
|
-64% |
|
| Mcgirr David W J |
Director |
– • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
51,667 |
|
- |
|
| De Craecker Francoise |
Director |
– • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
51,667 |
|
- |
|
| Bridger Gary |
Director |
– • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
51,667 |
|
- |
|
| Lawton Alison Francis |
Director |
– • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
51,667 |
|
- |
|
| Wyzga Michael S |
Director |
– • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
51,667 |
|
- |
|
| Aliski William |
Director |
– • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
51,667 |
|
- |
|
| Ragan Paula |
President and CEO |
• • – |
2023-05-31 |
4 |
AS |
$1.95 |
$12,269 |
D/D |
(6,292) |
557,245 |
|
-54% |
|
| Ragan Paula |
President and CEO |
• • – |
2023-03-10 |
4 |
AS |
$0.84 |
$41,730 |
D/D |
(49,678) |
563,537 |
|
111% |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2023-03-10 |
4 |
AS |
$0.84 |
$15,281 |
D/D |
(18,192) |
152,714 |
|
111% |
|
| Taveras Arthur |
Chief Scientific Officer |
• – – |
2023-03-10 |
4 |
AS |
$0.84 |
$14,117 |
D/D |
(16,806) |
86,373 |
|
111% |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2023-03-10 |
4 |
AS |
$0.84 |
$44,100 |
D/D |
(52,500) |
93,696 |
|
111% |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2023-02-13 |
4 |
AS |
$0.93 |
$25,781 |
D/D |
(27,721) |
146,196 |
|
107% |
|
| Ragan Paula |
President and CEO |
• • – |
2023-02-13 |
4 |
AS |
$0.93 |
$20,176 |
D/D |
(21,695) |
613,215 |
|
107% |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2023-02-13 |
4 |
AS |
$0.93 |
$4,044 |
D/D |
(4,348) |
170,906 |
|
107% |
|
| Taveras Arthur |
Chief Scientific Officer |
• – – |
2023-02-13 |
4 |
AS |
$0.93 |
$863 |
D/D |
(928) |
103,179 |
|
107% |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2022-08-17 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,713) |
177,896 |
|
-16% |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2022-08-17 |
4 |
AS |
$0.00 |
$0 |
D/D |
(10,834) |
173,917 |
|
-16% |
|
| Meisner Derek M |
Chief Legal Officer |
• – – |
2022-08-17 |
4 |
AS |
$0.00 |
$0 |
D/D |
(8,334) |
145,155 |
|
-16% |
|
| Ragan Paula |
President and CEO |
• • – |
2022-08-17 |
4 |
AS |
$0.00 |
$0 |
D/D |
(13,448) |
634,910 |
|
-16% |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2022-06-30 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,578) |
179,609 |
|
78% |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2022-06-30 |
4 |
AS |
$0.00 |
$0 |
D/D |
(2,641) |
184,751 |
|
78% |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2022-06-24 |
4 |
AS |
$0.00 |
$0 |
D/D |
(856) |
181,187 |
|
77% |
|
| Meisner Derek M |
Chief Legal Officer |
• – – |
2022-06-24 |
4 |
AS |
$0.00 |
$0 |
D/D |
(4,166) |
153,489 |
|
77% |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2022-06-24 |
4 |
AS |
$0.00 |
$0 |
D/D |
(5,416) |
187,392 |
|
77% |
|
160 Records found
|
|
Page 2 of 7 |
|
|
0.11 (9.17%) 
